{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,090.85",
    "chg": -9.45,
    "chgp": "-0.45%",
    "dir": -1,
    "prev_price": "2,100.30",
    "mcapval": "56,471.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE935A01035",
    "curr_date": "Apr 02",
    "curr_time": "",
    "bse_nse_vol": "10.22 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 02, 2026",
    "traded_date_str": "2026 04 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [],
    "total": 0,
    "sid": "780863",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "01-Apr-2026",
      "details": "Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS in the U.S. Significantly Expanding Its Innovative Portfolio. RYALTRIS is Glenmarks first innovative product introduced into the U.S. Market.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Regulatory Action/ Inspection",
      "datetime": "01-Apr-2026",
      "details": "Disclosure under Regulation 30 of the SEBI (LODR) Regulations 2015 - Regulatory action/Inspection",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "21-Mar-2026",
      "details": "Glenmark Pharmaceuticals Launches GLIPIQ (Semaglutide) in India. Setting a new benchmark in affordability for GLP-1 therapy with weekly treatment starting at Rs. 325",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 03 Oct 25",
          "dt": "2025-10-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

No Recent News for the Company

View All News